Exscientia initiates prospective observational study in ovarian cancer

Oxford, england & vienna, austria--(business wire)--exscientia plc (nasdaq: exai) today announced the initiation of excyte-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (evdr) in primary tumour-derived samples using the company's precision medicine platform and actual patient clinical response. this first of its kind observational study in solid tumours will run at multiple medical research centres in europe with a focus on.
EXAI Ratings Summary
EXAI Quant Ranking